T
Telomir Pharmaceuticals, Inc. (TELO)
NCM – Real Time Price. Currency in USD
1.26
-0.03 (-2.33%)
At close: May 12, 2026, 4:00 PM EDT
1.26
+0.00 (0.40%)
Pre-market: May 13, 2026, 7:00 AM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
1.26
-0.03 (-2.33%)
At close: May 12, 2026, 4:00 PM EDT
1.26
+0.00 (0.40%)
Pre-market: May 13, 2026, 7:00 AM EDT
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson’s disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer’s disease and Progeria. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.
| Name | Position |
|---|---|
| Dr. Itzchak Angel Ph.D. | Chief Scientific Advisor |
| Mr. Alan Weichselbaum CPA, M.B.A. | Chief Financial Officer |
| Mr. Erez Aminov | Chairman of the Board & CEO |
| Date | Type | Document |
|---|---|---|
| 2026-04-30 | 8-K | form8-k.htm |
| 2026-04-24 | 8-K | form8-k.htm |
| 2026-03-31 | 8-K | form8-k.htm |
| 2026-03-27 | 8-K | form8-k.htm |
| 2026-03-17 | 10-K | form10-k.htm |
| 2026-02-19 | DEFM14A | formdefm14a.htm |
| 2026-02-19 | DEFA14A | formdefa14a.htm |
| 2026-02-17 | 8-K | form8-k.htm |
| 2026-02-05 | PRER14A | formprer14a.htm |
| 2026-01-23 | PRER14A | formprer14a.htm |